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Development and clinical effects of chimeric 
antigen receptor (CAR)-T cells
Recent development of cancer immunotherapy, and CAR-T 
cell therapy in particular, attracts considerable attention 
among researchers. In antitumor immunity, cytotoxic T 
lymphocytes (CTLs) specifically recognize tumor-associated 
antigens (TAAs) in an MHC-class I-restricted manner and 
attack tumor cells. CTL activation and its clonal expansion 
require co-stimulatory receptors such as CD28, 4-1BB and 
OX40, and CTL stimulatory cytokine including IL-2 and 
IFNγ in addition to antigen recognition. However, tumor 
cells escape from the immune surveillance via decreased 
expression of MHC class 1, increased expression of co-
inhibitory molecule, inhibitory cytokine production and 
accumulation of inhibitory immune cells during in vivo 
growth. CAR gene-designated extracellular binding domain 
consists of a target-specific antibody or a targeting ligand 
fused with the intracellular activating CD3zeta chain and 
the co-stimulatory molecule gene (1). Unlike conventional 
activated lymphocyte therapy or natural adaptive immunity, 
genetically engineered CAR-T cells can attack tumor 
cells in non-MHC class 1-restricted manner without co-
stimulatory molecule signals. Complete remission and 
durable clinical effect of CD19 CAR-T cell therapy for 
CD19 positive leukemia are reported in previous studies (2). 
Treatment strategies using CAR-T cells have also been 
developed for high-grade gliomas (HGGs). IL-13Rα2 is a 
cell surface receptor, over-expressed in more than a half of 
HGG patients (3). IL-13 zetakine contains point-mutated 
IL-13 sequence and it does not bind to IL-13Rα1 but 
specifically binds to IL-13Rα2 (4). Therapeutic effects of 
IL-13 zetakine-transfected T cells have been reported in 
in vitro and in vivo studies using several cell lines containing 
a tumor stem cell line and isolated HGG cells (5,6). A 
case study of HGG patients treated with IL-13 zetakine 
transfected T cells showed safety of the cell injection and 
efficacy during clinical monitoring (7). In this study, CTLs, 
genetically modified to express the herpes simplex virus 1 
thymidine kinase (HSV1-tk) suicide gene, were injected in 
HGG patients, and HSV1-tk positive CTLs were detected 
by the PET scan with the uptake of a 18F radiolabelled 9-[4-
[18F] fluoro-3-(hydroxymethyl)butyl]guanine ([18F] FHBG) 
as a probe.
Determination of treatment effect—problems of 
prognosis estimation
Easy and exact method to predict therapeutic effect of 
these immunotherapies and patient prognosis has not been 
found to date. In general, detection of the delayed-type 
hypersensitivity (DTH) reaction using TAA is performed 
after immunotherapy. Also in our study, DTH-positive 
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patients have been found to experience a good prognosis (8). 
A recent study shows the correlation between preoperative 
PD-L1 expression of circulating mononuclear cells and 
prognosis after immunotherapy, and that is expected as a 
prognostic marker for immunotherapy (9). However, they 
are not real-time tools for evaluating treatment effect during 
immunotherapy. MR imaging is a repeatable imaging tool 
for detection of the treatment effect. Response evaluation 
criteria in solid tumors (RECIST) based on MR imaging 
are most frequently used for evaluation of the local reaction 
of antitumor therapy including chemotherapy. However, 
the use of these criteria for immunotherapy has some issues 
such as underestimation of progression-free survival due to 
pseudoprogression caused by the cell influx into the tumor 
microenvironment and no correlation with long-term 
prognosis (10). Although immune related response criteria 
(irRC) were advocated to solve these issues (11), it takes 
2–3 months for the first response assessment to determine 
the therapeutic effect, and patients lose treatment 
opportunity if true progression occurs during this period. 
For these reasons, development of a method of immune 
cells tracking and early therapeutic effect prediction has 
been urged. This non-invasive in vivo imaging of dynamics 
of immune cells in the human body has become available 
in clinical practice with the development of several new 
molecular imaging methods. It will be an important 
method to improve development and optimization of 
immunotherapy.
CTL Tracking using [18F] FHBG
[18F] FHBG is a PET tracer with an 18F-labelled side 
chain of penciclovir used for detecting HSV1-tk or HSV-
sr39tk mutant protein (12). [18F] FHBG is not degraded 
in mammalian TK and does not emit a radio signal. In 
preclinical models using rats and rabbits, [18F] FHBG 
showed to be safe after administration in doses 100 times 
higher than for humans, and it was approved by FDA as an 
investigational new drug (13). Yaghoubi et al. also studied 
human pharmacokinetics and dosimetry of [18F] FHBG 
with ten healthy volunteers and showed no toxicity (14). 
The safety and feasibility of radiolabeled [18F] FHBG 
PET is studied in several clinical fields including recurrent 
glioma (7,15). 
Keu et al. reported the in vivo kinetics of CAR-T cells 
detected by PET scan using [18F] FHBG (16). Genetically 
engineered IL-13 zetakine CAR-T cells were transfected 
with hygromycin phosphotransferases/HSV-tk fused in-
frame gene and glucocorticoid resistance locus. Those 
CAR-T cells were positively selected using hygromycin 
B and indirect labeling with [18F] FHBG. In addition, 
glucocorticoid receptor resistance locus allowed using 
that CAR-T cells in HGG patients during steroid 
therapy. Those sequences were transfected into CTL by 
electroporation using plasmid DNA. In this Keu’s study, 
7 patients including the first patient who administrated [18F] 
FHBG with relapsed/recurrent HGG were enrolled. These 
patients received autologous or allogeneic CAR-T cells, and 
in vivo monitoring was performed by the [18F] FHBG-PET 
scan. Safety and stability of CAR-T cells and [18F] FHBG 
were examined. Rickham reservoir/catheter was installed 
to reach the tumor resection site after surgery or biopsy 
and CAR-T cells were injected directly into the tumor site. 
Patients No. 1–2 administered autologous CAR-T cells and 
the patients No. 3–7 administered allogeneic CAR-T cells 
(GRm13Z40-2 CTL line) derived from healthy donors. 
Patients No. 3–7 simultaneously administered recombinant 
human IL-2. More than 99% of the produced CAR-T 
cells were CD8 positive T cells, and [18F] FHBG uptake 
of CAR-T cells was significantly higher than that of the 
parental cells. After the [18F] FHBG uptake, CAR-T cells 
retained proliferation ability for 2 days. 
One patient had rash and redness in the lower part of 
the face after administration of FHBG, but the symptoms 
improved after administration of diphenhydramine. There 
were no serious adverse events other than in this patient. 
After administration of [18F] FHBG, the [18F] FHBG 
accumulated in the tumor area and tumor resection site 
were observed. One patient whose tumor was attached 
to the dura matter with rich tumor blood vessels showed 
3–4 times higher accumulation of [18F] FHBG compared 
to the baseline. Since [18F] FHBG cannot pass through 
the BBB, [18F] FHBG accumulated in areas rich in tumor 
blood vessels without the BBB. PET scan data calculation 
methods need to be validated, however, an increase in 
signal was observed after the CAR-T cells administration 
in all patients except Patient 1, who could not receive pre-
CAR-T cell injection PET scan. Furthermore, in patients 
with multiple tumors an increase in [18F] FHBG signal was 
observed in areas where CTLs were not injected, suggesting 
transition of CAR-T cells between tumors. These data 
proved that PET scan with [18F] FHBG can visualize HSV1-
tk expressing CAR-T cells accumulated in the tumor site 
after injection. Data on safety of [18F] FHBG needs to be 
collected in the future. In this study, the compound targeted 
recurrent gliomas, and most patients died within 12 months 
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after administration of CAR-T cells. Further research will 
be focused on methods to evaluate the therapeutic effect of 
CAR-T cell therapy.
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